1. Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p<0.01; ‡p<0.05 vs placebo; missing values were imputed as non-response through week 16.
Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p<0.01; ‡p<0.05 vs placebo; missing values were imputed as non-response through week 16. MI presented from week 20 to 156 (shaded area) included n=56 and 103 in the normal baseline CRP and elevated baseline CRP groups, respectively. Data for secukinumab 150 mg and placebo at week 16 and for secukinumab 150 mg at week 156 are depicted. ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; MI, multiple imputation; N, number of patients with available baseline CRP (normal or elevated) included in this pooled study through week 16; n, number of patients in this pooled study from week 20 to 156.
Jürgen Braun et al. RMD Open 2018;4:e000749
Copyright © BMJ Publishing Group & EULAR. All rights reserved.